Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy

Authors: Bikorimana, Jean Pierre ^{1, 6}, Farah, Roudy ^{1, 6}, Abusarah, Jamilah ², Mandl, Gabrielle Arona ¹, Erregragui, Mohamed Ali ¹, Gonçalves, Marina Pereira ³, Talbot, Sebastien ⁴, Matar, Perla ¹, Lahrichi, Malak ³, El-Hachem, Nehme ⁵, Rafei, Moutih ^{1, 2, 3, 7, ∗}

Source: In iScience 21 March 2025 28(3)

A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses

Authors: Gonçalves, Marina Pereira, Farah, Roudy, Bikorimana, Jean-Pierre, Abusarah, Jamilah, EL-Hachem, Nehme, Saad, Wael, Talbot, Sebastien, Stanga, Daniela, Beaudoin, Simon, Plouffe, Sebastien, Rafei, Moutih

Source: In iScience 15 March 2024 27(3)

Local delivery of accutox^® synergises with immune-checkpoint inhibitors at disrupting tumor growth.

Authors: Bikorimana, Jean Pierre, El-Hachem, Nehme, Abusarah, Jamilah, Gonçalves, Marina Pereira, Farah, Roudy, Mandl, Gabrielle A., Talbot, Sebastien, Beaudoin, Simon, Stanga, Daniela, Plouffe, Sebastien, Rafei, Moutih

Source: Journal of Translational Medicine; 6/3/2024, Vol. 22 Issue 1, p1-16, 16p

Subject Terms: IMMUNE checkpoint inhibitors, TUMOR growth, ANTIGEN presentation, T-cell lymphoma, REACTIVE oxygen species

An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity.

Authors: Bikorimana, Jean‐Pierre, Abusarah, Jamilah, Gonçalves, Marina, Farah, Roudy, Saad, Wael, Talbot, Sebastien, Stanga, Daniela, Beaudoin, Simon, Plouffe, Sebastien, Rafei, Moutih

Source: Cancer Science; Apr2024, Vol. 115 Issue 4, p1102-1113, 12p